Oslo, Norway 26 June 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing next generation circular RNA vector technology for gene
therapy, today announces that CEO Dr. Erik Digman Wiklund and CSO Dr. Victor
Levitsky have been invited to speak at two upcoming biopharma industry RNA
conferences in Frankfurt, Germany, and San Diego, USA.

The European mRNA conference 2024 (https://europe.the-mrna
-conference.com/access/program)

Title: Is circular RNA surpassing mRNA as the RNA format for the future?

Time & place: 26 June 2024, 11:00 CEST, Frankfurt, Germany

Presenter: Dr. Victor Levitsky, CSO

RNA Leaders USA Congress (https://informaconnect.com/rna-leaders-usa/agenda/1/)

Title: Deploying circular RNA expression to boost gene therapy - AAV and beyond

Time & place: 4 September 2024, 15:05 PST, San Diego, USA

Presenter: Dr. Erik Digman Wiklund, CEO

These invitations to present at important RNA industry conferences place Circio
along other leading RNA companies, such as Moderna, Biontech and oRNA
Therapeutics. The presentations will provide an important forum to highlight the
advantages and potential of circular RNA and reinforce CircioŽs position as
discoverers and leaders in this rapidly emerging field.

The presentations will be made available on CircioŽs webpage on the respective
dates.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform for genetic
medicine. The proprietary circVec technology is based on a modular genetic
cassette design for efficient biogenesis of multifunctional circRNA from DNA and
viral vectors, which can be deployed in multiple disease settings. The circVec
platform has demonstrated enhanced and more durable protein expression than
classic mRNA vector systems and has the potential to become the new gold
-standard for DNA and virus-based therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.